Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer

A breast cancer, therapy technology, used in drug combinations, antibody medical components, biomaterial analysis, etc.

Inactive Publication Date: 2014-09-24
F HOFFMANN LA ROCHE & CO AG
View PDF15 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The underlying mechanism of unresponsiveness remains unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
  • Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
  • Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0009] 1. Definition

[0010] As used herein, the term "administering" or "administering" means administering a pharmaceutical composition, such as an angiogenesis inhibitor, to a patient in need of such treatment or medical intervention by any suitable means known in the art. Non-limiting routes of administration include oral, intravenous, intraperitoneal, subcutaneous, intramuscular, topical, intradermal, intranasal or intrabronchial administration (eg, by inhalation). Particularly preferred in the context of the present invention is parenteral administration, eg intravenous administration.

[0011] The terms "anti-angiogenic agent" or "angiogenesis inhibitor" refer to small molecular weight substances, polynucleotides, which either directly or indirectly inhibit angiogenesis, vasculogenesis or unwanted vascular permeability, Polypeptides, isolated proteins, recombinant proteins, antibodies, or conjugates or fusion proteins thereof. It is understood that anti-angiogenic ag...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin TM ) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of VEGFA and / or VEGFR2 relative to control levels of patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer. The present invention also provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin TM ) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of VEGFA and / or VEGFR2 relative to control levels in patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer.

Description

field of invention [0001] The present invention is directed to methods for identifying which patients diagnosed with HER2-positive breast cancer would most benefit from treatment with an anti-cancer therapy comprising an anti-VEGF antibody. Background of the invention [0002] Angiogenesis contributes to benign and malignant diseases such as cancer formation and, especially in cancer, is required for primary tumor growth, invasion and metastasis. In order to grow, tumors must undergo an angiogenic switch. Vascular endothelial growth factor (VEGF) is required to induce this angiogenic switch. VEGF and genes in the VEGF pathway are considered important mediators of cancer progression. The VEGF gene family includes the VEGF gene (also known as VEGFA), homologues of VEGF including placental growth factor (PlGF), VEGFB, VEGFC, VEGFD, VEGF receptors including VEGFR-1 and VEGFR-2 (also known as FLT1 and FLK1 / KDR), VEGF inducers, including hypoxia inducible factors HIF1α, HIF2α, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574
CPCC07K16/22G01N2333/475G01N33/57415A61K31/337A61K39/39558A61P35/00
Inventor H.安德里斯S.L.德哈斯R.艾利奥特J.卡尔Y-J.G.孟G.D.普罗曼S.谢尔N.怀尔德
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com